GSK shipping record number of flu vaccine doses for upcoming season

Press enter to search
Close search
Open Menu
A pharmacist giving a vaccine.

GSK shipping record number of flu vaccine doses for upcoming season

By Sandra Levy - 07/29/2020

GSK has started shipping its quadrivalent influenza vaccines to U.S. healthcare providers and pharmacies for the 2020-2021 flu season. This immediately follows a licensing and lot-release approval from the Food and Drug Administration's Center for Biologics Evaluation and Research.

GSK is producing the largest supply ever as CDC urges adults and high-risk individuals to be immunized against influenza during the COVID-19 pandemic. 

In fact, GSK expects to supply more than 50 million doses of its influenza vaccines for the U.S. market in the 2020-2021 season, an increase from the 46 million it distributed during the 2019-2020 influenza season. With shipments this season, GSK will cross the 1 billion doses manufactured globally milestone during the company's history.

"The flu is a serious and unpredictable disease that causes tens of millions of illnesses, hundreds of thousands of hospitalizations and tens of thousands of deaths in the United State each year," said Judy Stewart, senior vice president, U.S. vaccines. "GSK is looking at every opportunity to produce and distribute additional flu vaccines this upcoming season to meet anticipated demand. We are working closely with public health partners to improve flu immunization rates to reduce the spread of disease and burden on the healthcare system during the ongoing public health challenge presented by the COVID-19 pandemic."

The Centers for Disease Control and Prevention recommends that everyone 6 months of age and older get a flu vaccine every season. In recent weeks, the CDC has repeatedly emphasized the importance of influenza vaccination this flu season to help reduce the burden of disease and the impact of influenza on the healthcare system and other critical infrastructures during the COVID-19 pandemic.

"Many people have fallen behind on their routine immunizations during the COVID-19 stay-at-home orders with immunization rates declining for children, adolescents and adults," said Leonard Friedland, GSK vice president, director of scientific affairs and public health, vaccines. "The CDC has urged individuals to maintain or reinitiate routine immunization across the lifespan to prevent illnesses that could lead to unnecessary medical visits, hospitalization and further strain on the healthcare system. As we head into flu season, it's important to not only get a flu vaccine, but to prioritize getting caught up on all CDC-recommended vaccines, particularly for adults and vulnerable populations."

Both Flulaval Quadrivalent and Fluarix Quadrivalent will be available in a 0.5mL, single-dose, pre-filled syringe, and indicated for patients 6 months and older in line with CDC recommendations.